Retatrutide
RT10 · 10mg · 2026-08-16 · N/A
COA PDF ↗
RT10Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Retatrutide
Obesity and weight reduction
Retatrutide specifications and reference prices. Select a specification to add it to your cart.
10mg/vial x 10vials
Reference priceUS$109.09
For laboratory research only. Not for human or veterinary use.
COA 检测报告 / Reports
Compare all specifications & reference prices
| SKU | Specification / pack | Reference price (USD) |
|---|---|---|
| RT5 | 5mg/vial x 10vials | US$63.64 |
| RT10 | 10mg/vial x 10vials | US$109.09 |
| RT15 | 15mg/vial x 10vials | US$157.58 |
| RT20 | 20mg/vial x 10vials | US$184.85 |
| RT30 | 30mg/vial x 10vials | US$260.61 |
| RT40 | 40mg/vial x 10vials | US$333.33 |
| RT50 | 50mg/vial x 10vials | US$400 |
| RT60 | 60mg/vial x 10vials | US$496.97 |
| RT100 | 100mg/vial x 10vials | US$696.97 |
| RT120 | 120mg/vial x 10vials | US$818.18 |
Temporarily sold-out specifications can still be added to an inquiry to ask about restocking. An inquiry is not an order or an agreed price.
DOCUMENTATION / RT10
Retatrutide — supplied COA and inquiry notes
The Retatrutide catalog group currently lists 10 specifications. Use the selector and specification table above to compare SKUs and reference prices. The linked report identifies sample RT10; its sample code is not a separate specification selection.
- Report sample code
- RT10
- Reported date
- 2026-08-16
- Sample purity (HPLC-UV)
- 99.14%
- Sample net content
- 10.82 mg
- Lot / batch field
- N/A
- Endotoxin result
- N/A
These values describe the supplied test sample only.
When inquiring about Retatrutide, include the exact SKU, pack quantity and destination. Ask for stock and batch-document confirmation. Temporarily sold-out specifications can still be queried; the cart is not a confirmed order.
For laboratory research only. Not for human or veterinary use. The supplied report footnotes also exclude diagnostic, therapeutic and clinical applications.
Explore GLP-1 & Metabolic Research ↗ · View all products
RESEARCH FOCUS
Main Uses & FAQs
This page organizes directly related information on Retatrutide regarding obesity and weight loss. First, look at research questions and findings, then verify the population or species, study formulations, and scope of interpretation.
Main TopicsObesity · Weight loss
USAGE REFERENCE
Retatrutide · Usage reference (for research purposes)
The following presents common research-context references for reconstitution, storage, dosage and cycles. The following presents common references in research settings. This page does not constitute advice for use in humans or animals.
🧪Reconstitution
- Suggested Diluent
- Bacteriostatic Water (containing 0.9% benzyl alcohol); some peptides may use sterile water or acetic acid to aid dissolution. See the individual product descriptions.
- Diluent Volume
- Slowly introduce the diluent along the vial wall until the lyophilized powder is covered. A common example is 5 mg reconstituted with 2 mL of bacteriostatic water, yielding approximately 2.5 mg/mL. Referenced reconstitution volumes are approximately 1–2.5 mL, with 2 mL commonly used. It is suggested to select and record a fixed volume based on the COA supplied with the purchase.
- Handling Notes
- Introduce the diluent slowly along the vial wall rather than directly onto the lyophilized powder. Leave it for 60–90 seconds to dissolve naturally; do not shake vigorously.
💾Storage
- Unreconstituted Lyophilized Powder
- Refrigerate at 2–8°C, protected from light; avoid repeated freeze–thaw cycles.
- After Reconstitution
- Refrigerate at 2–8°C; a common recommendation is touse within 28 days; do not freeze.
- Transport
- For short periods, use insulated packaging with ice packs; avoid high temperatures and direct light.
📏Dosage Reference (Research)
| Purpose / Setting | Common Reference |
|---|---|
| Administration Route | Subcutaneous injection |
| Frequency | Once weekly |
Note: The above describes common research-context references, rather than clinical recommendations. Refer to the batch COA and research protocol. For research use only; not for human or animal use.
References
Read the Full Research Review ↗Research SummaryKey Findings
What research findings exist for Retatrutide in obesity and weight loss?
Obesity combined with type 2 diabetes patients showed improvement in weight and blood glucose control at 80 weeks. Other studies reported significant weight loss in obese adults; Specific knee osteoarthritis and sleep apnea subgroups also showed improvement.[1] ↗ [2] ↗
Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
Human Study2026REF. 01
What findings emerged from weight studies in populations with diabetes?
Research Findings
Obesity combined with type 2 diabetes patients showed improved weight and blood glucose control at 80 weeks.[1] ↗
Study Design
Randomized Double-Blind Placebo-Controlled Phase III in Humans; TRIUMPH-2
Scope & Limitations
Experimental Medication and Specific Inclusion Criteria; Cannot Be Converted into Commercial Use Commitment.
View the Article Title and Full Citation＋
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
Lancet (London, England) · Volume, issue, year 2026
First published 2026-09-29 · PMID 42810372
DOI 10.1016/S0140-6736(26)01861-1
Human Study2026REF. 02
What was observed in phase III obesity studies?
Research Findings
Obese adults experienced significant weight loss; Certain knee osteoarthritis and sleep apnea subgroups also showed improvement.[2] ↗
Study Design
Human randomized, double-blind Phase III; TRIUMPH-1
Scope & Limitations
Some OSA papers share the mother trials, so they cannot be considered as fully independent replication.
View the Article Title and Full Citation＋
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
The New England Journal of Medicine · Volume, Issue, Year 2026
First published 2026-09-29 · PMID 42814954
DOI 10.1056/NEJMoa2604169
Human Study2025REF. 03
What does DXA body composition analysis supplement?
Research Findings
Some study dose groups showed total fat reduction better than placebo, supplementing evidence of body composition beyond weight.[3] ↗
Study Design
Adults with type 2 diabetes; Retatrutide Phase II DXA body composition sub-study
Scope & Limitations
Not every dose shows significant effects; only some subjects completed pre- and post-DXA, so it cannot be considered pure fat loss without lean mass loss.
View the Article Title and Full Citation＋
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
The Lancet. Diabetes & Endocrinology · Volume and issue year 2025
First published 2025-06-30 · PMID 40609566
DOI 10.1016/S2213-8587(25)00092-0
Human Study2023REF. 04
How much weight loss was shown in early dose exploration?
Research Findings
Retatrutide weight loss in all study dose groups was superior to placebo, with the highest dose group showing an average decrease of 24.2% at 48 weeks.[4] ↗
Study Design
338 overweight or obese adults; 48-week randomized double-blind Phase II trial
Scope & Limitations
Dose exploration trial showed gastrointestinal reactions and heart rate changes; not individual effects or bottle dose recommendations.
View the Article Title and Full Citation＋
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
The New England Journal of Medicine · Volume, Issue, Year 2023
First published 2023-06-26 · PMID 37366315
DOI 10.1056/NEJMoa2301972
Currently, 4 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
GO DEEPER
↗What Questions Do These Studies Address?
Compare study populations, findings and scope.
Retatrutide · Frequently Asked Questions.
What research findings exist for Retatrutide in obesity and weight loss?＋
Obesity combined with type 2 diabetes patients showed improvement in weight and blood glucose control at 80 weeks. Other studies reported significant weight loss in obese adults; Specific knee osteoarthritis and sleep apnea subgroups also showed improvement.[1] ↗ [2] ↗
Has Retatrutide been directly studied for fat mass?＋
Yes. DXA sub-studies in type 2 diabetes populations showed that some dose groups had more pronounced reductions in total fat; this is a body composition sub-study in a specific population and cannot be used to promise complete preservation of lean body mass.[3] ↗
Retatrutide—these conclusions apply to which study populations?＋
Human randomized, double-blind, placebo-controlled Phase III; TRIUMPH-2； Randomized, double-blind, Phase III human trial; TRIUMPH-1； Adults with type 2 diabetes; Retatrutide Phase II DXA body component study. Investigational drug and specific inclusion criteria; No conversion to commercial use commitment.[1] ↗ [2] ↗ [3] ↗
VENTRO PEPTIDES & BIOTECH · RESEARCH PRODUCT RETAIL
Research peptides. Shop by product.
Compare specifications, reference prices and COA reports. Add products to your cart to request a quote.
QUALITY DOCUMENTSCOA BY PRODUCTGLOBAL DELIVERYTECHNICAL SUPPORT
01 / CATALOG
Browse products
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Semaglutide
10mg/vial x 10vials
US$90.91
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Tirzepatide
20mg/vial x 10vials
US$160.61Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Retatrutide
10mg/vial x 10vials
US$109.09
Images are illustrative. Actual specifications are as selected and confirmed in writing.
Repair & Recovery Research
BPC157
10mg/vial x 10vials
US$133.33
Images are illustrative. Actual specifications are as selected and confirmed in writing.
Longevity & Mitochondrial Research
MOTS-C
20mg/vial x 10vials
US$257.58
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
Liraglutide
10mg*10vials
US$164.71
Images are illustrative. Actual specifications are as selected and confirmed in writing.
Growth Hormone & IGF-1
IGF-lr3
1mg/vial x 10vials
US$505.8802 / DISCOVER
Browse categories
01 / 04
03 / ABOUT VENTRO
Reliable peptide supply, built for long-term partnerships.
Ventro supports research product retail purchases with clear pack specifications, available quality documents, and responsive international support.
- High-purity peptides
- Available COA reports
- COA & quality documentation
- Flexible small-quantity purchases
- Reliable global fulfillment
- Research product retail support
04 / QUALITY SYSTEM
Quality without compromise
Browse the available COA reports by product. Confirm documentation for your order with our team.
Controlled quality workflowRaw material to final release
Responsive global supportProduct matching and technical support
RESEARCH PRODUCT INQUIRY
Submit a product inquiry
Tell us the product, specification, and expected quantity. Our team will respond with pricing and available documents.